|
1) Egrie JC, Dwyer JR, Lykos M, et al. Novel erythropoiesis stimulating protein (NESP) has a longer half-life and greater in vivo biological activity compared to recombinant human erythropoietin(rHuEPO). Blood. 1997; 90: 56A (abst)
|
|
|
|
|
2) Macdougall IC. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant. 2001; 16 (Suppl 3): 14-21
|
|
|
|
|
3) Jacob A, Sandhu K, Nicholas J, et al. Antibody-mediated pure red cell aplasia in a dialysis patient receiving darbepoetin alfa as the sole erythropoietic agent. Nephrol Dial Transplant. 2006; 21: 2963-5
|
|
|
|
|
4) The NESP usage guidelines group. Practical guidelines for the use of NESP in treating renal anaemia. Nephron Dial Transplant. 2001; 16 (Suppl 3): 22-8
|
|
|
|
|
|
5) Macdougall IC. CERA(Continuous Erythropoietin Receptor Activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Current Hematology Reports. 2005; 4: 436-40
|
|
|
|
|
|
6) Tillmann HC, Kuhn B, Kranzlin B, et al. Efficacy and immunogenicity of novel erythropoietic agents and conventional rhuEPO in rats with renal insufficiency. Kidney Int. 2006; 69: 60-7
|
|
|
|
|
|
7) Livnah O, Stura EA, Johnson DL, et al. Functional mimicry of a protein hormone by a peptide agonist: The EPO receptor complex at 2. 8Å. Science. 1996; 273: 464-71
|
|
|
|
|
|
8) Fan Q, Leuther KK, Holmes CP, et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol. 2006; 34: 1303-11
|
|
|
|
|
|
9) Woodburn KW, Fan Q, Leuther K, et al. Preclinical evaluation of HematideTM, a novel erythropoietic receptor agonist for the treatment of anemia caused by kidney disease. ASH: 2004; Abs#2904
|
|
|
|
|
|
10) Woodburn K, Schatz P, Fong K, et al. Preclinical safety, pharmacology and pharmacokinetic evaluation of HematideTM, a PEGylated peptidic erythropoiesis stimulating agent (ESA), for the correction of anemia in patients with kidney disease. ASN: 2006; Abs#TH-PO359
|
|
|
|
|
|
11) Woodburn K, Schatz P, Fong K, et al. Chronic preclinical safety evaluation of hematideTM, a PEGylated peptidic erythropoiesis stimulating agent (ESA), in monkeys. ASH. 2006; Abs#1155
|
|
|
|
|
|
12) Stead RB, Lambert J, Wessels D, et al. Evaluation of the safety and pharmacodynamics of Hema-tide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood. 2006; 108: 1830-4
|
|
|
|
|
|
13) Maxwell PH. Hypoxia-inducible factor as a physiological regulator. Exp Physiol. 2005; 90: 791-7
|
|
|
|
|
|
14) Urquilla P, Fong A, Oksanen S, et al. Up-regulation of endogenous EPO in healthy subjects by inhibition of hypoxia-inducible factor (HIF) prolylhydroxylase. Blood. 2004; 104: 54A-174A
|
|
|
|
|
|
15) Gunzler V, Muthukrishnan E, Neumayer HH, et al. FG2216 increases hemoglobin concentration in anemic patients with chronic kidney disease. Am Soc Nephrol Renal Week. 2005: AbsSA-PO0924
|
|
|
|
|
|
16) Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3: 721-32
|
|
|
|
|
|
17) Langsetmo I, Nichols B, Seeley E, et al. FG-2216 corrects anemia and improves iron utilization in a rat model of anemia of chronic disease: com-parison to darbepoetin. Am Soc Nephrol. Renal Week. 2005; Abst SA-PO0674
|
|
|
|
|
|
18) Johnson DW, Forman C, Vesey DA. Novel renoprotective actions of erythropoietin: new users for an old hormone. Nephrology. 2006; 11: 306-12
|
|
|
|
|
|
19) Date T, Mochizuki S, Belanger AJ, et al. Expression of constitutively stable hybrid hypoxia-inducible factor-1 alfa protects cultured rat cardiomyocytes against stimulated ischemia-reperfusion injury. Am J Physiol Cell Physiol. 2005; 288: C314-20
|
|
|
|
|
|
20) Ratan RR, Siddiq A, Aminova L, et al. Translation of ischemic preconditioning to the patient: prolylhydroxylase inhibition and hypoxia induci-ble factor-1 as novel targets for stroke therapy. Stroke. 2004; 35: 2687-9
|
|
|
|
|
|
21) European best practice guideline II working group: European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004; 19 (Suppl 2): S2-47
|
|
|
|
|
|
22) NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: (http://www.kidney.org/professionals/KDOQI/guidelines_anemia/cpr31). 2006
|
|
|
|
|
|
23) 日本透析医学会. 慢性血液透析患者における腎性貧血治療のガイドライン. 透析会誌. 2004; 37: 1737-63
|
|
|
|
|
|
24) 日本透析医学会統計調査委員会. 図説 わが国の慢性透析療法の現況, 2006年末現在, 日本透析医学会. 2007 (http://docs.jsdt.or.jp/overview/index.html)
|
|
|
|
|